Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Illumina, Inc.. (1/7/16). "Press Release: Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT". San Diego, CA.

Region Region United Kingdom (GB)
Organisations Organisation Illumina Inc. (Nasdaq: ILMN)
  Group Illumina (Group)
  Organisation 2 Premaitha Health plc (AIM: NIPT)
  Group Premaitha Health (Group)
Products Product Harmony™ Prenatal Test
  Product 2 IONA® Test (genomic prenatal maternal blood test)
Person Person Chambers, Rebecca (Illumina 201602 Investor Relations)
     


Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two patent infringement suits in Europe. The patents asserted use cell-free fetal DNA for non-invasive prenatal testing (NIPT).

The first suit was filed against The Doctors Laboratory Ltd, TDL Genetics Ltd, and Ariosa Diagnostics, Inc. in the High Court of Justice, Chancery Division in the United Kingdom. The suit accuses The Doctors Laboratory and TDL Genetics’ use of the Harmony™ NIPT test supplied by Ariosa of infringing European Patent 0 994 963.

The second suit was filed against Centrum Badan Sp z o.o. and Medgenetix Sp z o.o. in the Regional Court in Warsaw, Poland. The suit accuses Centrum and Medgenetix’s use of the Iona® NIPT test supplied by Premaitha Health PLC of infringing European Patent 2 183 693.

Illumina is seeking all available remedies, including damages and injunctive relief.

These new lawsuits follow suits previously filed against Ariosa in the United States and Premaitha in the United Kingdom.


About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
or
David Robertson, Europe, Middle East and Africa
+44 1223 824909
drobertson@illumina.com

   
Record changed: 2018-09-19

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Illumina (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top